|
gptkbp:instanceOf
|
gptkb:drug
immunotherapy
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L04AA27
|
|
gptkbp:bioavailability
|
93%
|
|
gptkbp:brand
|
gptkb:Gilenya
|
|
gptkbp:CASNumber
|
gptkb:162359-55-9
|
|
gptkbp:chemicalFormula
|
derived from myriocin
|
|
gptkbp:contraindication
|
stroke
recent myocardial infarction
second-degree or higher AV block
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
immunosuppressant
|
|
gptkbp:eliminationHalfLife
|
6-9 days
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstBook
|
oral disease-modifying therapy for multiple sclerosis
|
|
gptkbp:genericName
|
yes
|
|
gptkbp:hasMolecularFormula
|
C19H33NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fingolimod
|
|
gptkbp:interactsWith
|
gptkb:ketoconazole
beta-blockers
class Ia and III antiarrhythmics
|
|
gptkbp:KEGGID
|
D08968
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
sphingosine-1-phosphate receptor modulator
|
|
gptkbp:MeSH_ID
|
C521842
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
first dose cardiac monitoring
|
|
gptkbp:patentExpired
|
2019 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:PubChem_CID
|
gptkb:DB08868
gptkb:CHEMBL1178
97013
107964
|
|
gptkbp:riskFactor
|
gptkb:progressive_multifocal_leukoencephalopathy
increased risk of infections
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:lymphopenia
gptkb:macular_edema
bradycardia
liver enzyme elevation
|
|
gptkbp:synonym
|
gptkb:FTY720
|
|
gptkbp:UNII
|
G9200DO99Z
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Gilenya
|
|
gptkbp:bfsLayer
|
5
|